With $161.3 million over the next five years, NIH plans to expand the Pharmacogenomics Research Network, the agency reports. The network had been working on linking genetic variants to cancer, heart disease, asthma, and among others and now will also include research into rheumatoid arthritis and bipolar disorder. The new awards include 14 research grants, with projects ranging from pharmacogenomics in rural areas ranging to the pharmacogenomics of mood stabilizers, as well as seven resource awards.